DOYLESTOWN, PA — Sterotherapeutics has initiated a Phase 2 clinical trial for ST-002, an innovative drug candidate aimed at treating Cushing’s Syndrome, a rare and severe endocrine disorder.

The Phase 2 clinical trial aims to evaluate the safety, efficacy, and tolerability of ST-002 in patients with Cushing's syndrome. Cushing's syndrome is a rare and serious endocrine disorder caused ...

US-based clinical-stage company Sterotherapeutics has announced the commencement of a Phase II clinical trial for its drug candidate, ST-002, for treating Cushing's Syndrome, a rare endocrine ...

Agents that directly lower ACTH secretion by a pituitary adenoma represent an attractive option for the treatment of Cushing's disease, as these drugs directly target the pathogenesis of disease.

Corcept Therapeutics (CORT) announced the initiation of MOMENTUM, a clinical trial examining the prevalence of endogenous ...

DOYLESTOWN, Pa., Feb. 24, 2025 /PRNewswire/ -- Sterotherapeutics, a leading biopharmaceutical company dedicated to advancing innovative therapies, is announcing the launch of a Phase 2 clinical ...

As treatment with mifepristone results in an increase in ACTH in patients with Cushing's disease, pairing it with an ACTH modulator may prove useful. Ketoconazole may also represent a logical ...

Nick Cushing joined the squad last Tuesday after Gareth Taylor was sacked It's been some week for Manchester City interim manager Nick Cushing. After enduring a painful defeat by Chelsea in the ...